X0508 4 2025-10-24 0001595097 Corbus Pharmaceuticals Holdings, Inc. CRBP 0001626003 Cohen Yuval C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE NORWOOD MA 02062 true true false false Chief Executive Officer true Common Stock, par value $0.0001 per share 2025-10-24 4 M false 18660 4.26 A 156847 D Common Stock, par value $0.0001 per share 2025-10-24 4 S false 18660 17.01 D 138187 D Common Stock, par value $0.0001 per share 2025-10-27 4 M false 8973 4.26 A 147160 D Common Stock, par value $0.0001 per share 2025-10-27 4 S false 8973 17.14 D 138187 D Stock options (right to buy) 4.26 2025-10-24 4 M false 18660 0 D 2024-02-13 2033-02-13 Common Stock 18660 31079 D Stock options (right to buy) 4.26 2025-10-27 4 M false 8973 0 D 2024-02-13 2033-02-13 Common Stock 8973 22106 D This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. /s/Yuval Cohen 2025-10-27